FI95712B - Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi - Google Patents

Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi

Info

Publication number
FI95712B
FI95712B FI882007A FI882007A FI95712B FI 95712 B FI95712 B FI 95712B FI 882007 A FI882007 A FI 882007A FI 882007 A FI882007 A FI 882007A FI 95712 B FI95712 B FI 95712B
Authority
FI
Finland
Prior art keywords
steroid
reductase
inhibitors
preparation
Prior art date
Application number
FI882007A
Other languages
English (en)
Swedish (sv)
Other versions
FI882007A0 (fi
FI882007A (fi
FI95712C (fi
Inventor
Dennis Alan Holt
Conrad John Kowalski
Mark Alan Levy
Brian Walter Metcalf
Ann Marie Tickner
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26720806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI95712(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of FI882007A0 publication Critical patent/FI882007A0/fi
Publication of FI882007A publication Critical patent/FI882007A/fi
Priority to FI943835A priority Critical patent/FI109028B/fi
Publication of FI95712B publication Critical patent/FI95712B/fi
Application granted granted Critical
Publication of FI95712C publication Critical patent/FI95712C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI882007A 1987-04-29 1988-04-28 Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi FI95712C (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI943835A FI109028B (fi) 1987-04-29 1994-08-19 Välituotteet käytettäväksi steroidi-5-alfa-reduktaasin inhibiittoreiden valmistamiseksi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4377387A 1987-04-29 1987-04-29
US07/127,147 US4910226A (en) 1987-04-29 1987-12-01 Steroid 5-alpha-reductase inhibitors

Publications (4)

Publication Number Publication Date
FI882007A0 FI882007A0 (fi) 1988-04-28
FI882007A FI882007A (fi) 1988-10-30
FI95712B true FI95712B (fi) 1995-11-30
FI95712C FI95712C (fi) 1996-03-11

Family

ID=26720806

Family Applications (1)

Application Number Title Priority Date Filing Date
FI882007A FI95712C (fi) 1987-04-29 1988-04-28 Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi

Country Status (23)

Country Link
US (1) US4910226A (fi)
EP (1) EP0289327B1 (fi)
JP (1) JPH0745511B2 (fi)
KR (1) KR0131207B1 (fi)
CN (2) CN1026236C (fi)
AU (1) AU615439B2 (fi)
CA (1) CA1327352C (fi)
CY (1) CY1822A (fi)
DE (1) DE3866938D1 (fi)
DK (1) DK175522B1 (fi)
ES (1) ES2039278T3 (fi)
FI (1) FI95712C (fi)
GR (1) GR3003768T3 (fi)
HK (1) HK22695A (fi)
HU (2) HU201956B (fi)
IE (1) IE60545B1 (fi)
IL (1) IL86185A (fi)
MY (1) MY103518A (fi)
NO (1) NO172586C (fi)
NZ (1) NZ224377A (fi)
PH (1) PH25963A (fi)
PT (1) PT87380B (fi)
ZW (1) ZW4488A1 (fi)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
JP2675418B2 (ja) * 1988-05-25 1997-11-12 スミスクライン・ベックマン・コーポレイション 芳香族ステロイド５‐α‐レダクターゼ抑制剤
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970204A (en) * 1989-08-23 1990-11-13 Smithkline Beecham Corporation 3-substituted nitro-steroid derivatives as 5-α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5100917A (en) * 1989-12-29 1992-03-31 Merrell Dow Pharmaceuticals Inc. Novel a-nor-steroid-3-carboxylic acid derivatives
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5075450A (en) * 1990-06-28 1991-12-24 Merck & Co., Inc. Intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes
EP0465123A3 (en) * 1990-06-28 1992-05-06 Merck & Co. Inc. New intermediates in the synthesis of 17beta-acyl-3-carboxy-androsta-3,5-dienes
CA2045866A1 (en) * 1990-06-28 1991-12-29 Gary H. Rasmusson 17-beta-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5 alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
GB9206414D0 (en) * 1992-03-24 1992-05-06 Smithkline Beecham Corp N-t-butyl-androst-3,5-diene-17b-carboxamide-3-carboxylic acid polymorph b
GB9206413D0 (en) * 1992-03-24 1992-05-06 Smithkline Beecham Corp N-t-butyl-androst-3,5-diene-17b-carboxamide-3-carboxylic acid polymorph a
ES2105108T3 (es) * 1992-04-20 1997-10-16 Sankyo Co Esteroides para el tratamiento de la hipertrofia prostatica, su preparacion y su utilizacion.
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
EP0646007B1 (en) * 1992-05-20 1997-08-13 Merck & Co. Inc. NEW DELTA-17 AND DELTA-20 OLEFINIC AND SATURATED 17$g(b)-SUBSTITUTED-4-AZA-5$g(a)-ANDROSTAN-3-ONES AS 5$g(a)-REDUCTASE INHIBITORS
RU94046044A (ru) * 1992-05-20 1996-10-10 Мерк Энд Ко. Новые 7 бета -замещенные 4-аза- 5 альфа -холестан-оны в качестве ингибиторов 5 альфа -редуктазы, фармацевтическая композиция на их основе, способ ее получения
EP0641204B1 (en) * 1992-05-20 2000-08-16 Merck & Co. Inc. 17-ethers and thioethers of 4-aza-steroids
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
AU675225B2 (en) * 1992-05-20 1997-01-30 Merck & Co., Inc. 17-amino substituted 4-azasteroid 5alpha-reductase inhibitors
DE69329856D1 (de) * 1992-05-20 2001-02-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
ATE195129T1 (de) * 1992-05-20 2000-08-15 Merck & Co Inc 4-azasteroide als 5-alpha-reduktase
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
AP9300589A0 (en) * 1992-11-18 1994-01-31 Smithkline Beecham Corp Novel 17a and 17b substituted acyl-3-carboxy 3,5-diene steroidal compounds, pharmaceutical compositions containing these compounds, and methods for using these compounds to inhibit steroid 5-a-reductase.
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
AU6413594A (en) * 1993-03-24 1994-10-11 Merck & Co., Inc. Substituted 3-phenanthridinone derivatives as 5alpha-reductase inhibitors
WO1994022897A1 (en) * 1993-04-02 1994-10-13 Ciba-Geigy Ag 17β-SUBSTITUTED ANDROSTA-3,5-DIENE DERIVATIVES
JP3325026B2 (ja) * 1993-06-28 2002-09-17 メルク エンド カンパニー インコーポレーテッド ４−アザ−プレグナン５α−レダクターゼアイソザイム１阻害剤
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
GB2282324A (en) * 1993-10-01 1995-04-05 Merck & Co Inc 17ß-Acyl-3-Carboxy-Androsta-3,5-dienes as anti-androgenic alopecia agents
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
FR2724174B1 (fr) * 1994-09-06 1997-01-17 Roussel Uclaf Procede de preparation d'un derive steroide 17beta-carboxy et nouveaux intermediaires
AU3826095A (en) * 1994-10-05 1996-05-02 Smithkline Beecham Corporation Process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1422234A3 (en) * 1999-03-23 2010-12-08 Harbor BioSciences, Inc. Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
KR100717897B1 (ko) * 1999-03-23 2007-05-14 홀리스-에덴 파마슈티칼즈, 인코포레이티드 면역 조절용 스테로이드, 특히16α-브로모에피안드로스테론의 헤미하이드레이트
JP2000309599A (ja) 1999-04-13 2000-11-07 Kyowa Hakko Kogyo Co Ltd エストラ−１，３，５（１０），１６−テトラエン誘導体
CA2522784C (en) 2003-04-01 2012-06-19 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
US7326717B2 (en) * 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US20060193804A1 (en) * 2005-02-24 2006-08-31 L'oreal Haircare use of cyclic amine derivatives
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
CN100355772C (zh) * 2005-12-28 2007-12-19 天津大学 具有5α－还原酶抑制活性的甾体化合物及其制备方法
EP1897533A1 (en) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
FR2929117B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929118B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
US9790233B2 (en) 2012-04-16 2017-10-17 Case Western Reserve University Compositions and methods of modulating 15-PGDH activity
EP3057973B1 (en) 2013-10-15 2019-09-04 Case Western Reserve University Compositions comprising a 15-pgdh inhibitor for the healing of wounds
WO2016090373A1 (en) 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CR20210328A (es) 2018-11-21 2021-12-02 Univ Case Western Reserve Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用
KR20230053551A (ko) 2020-05-20 2023-04-21 로데오 테라퓨틱스 코포레이션 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3129233A (en) * 1961-08-28 1964-04-14 American Home Prod 17beta-acetoxy-3-chloro-3, 5-androstadiene
US3530170A (en) * 1968-09-04 1970-09-22 Du Pont Selected 2-acyl-a-nor-5alpha-androstane derivatives
JPS539216B2 (fi) * 1973-11-28 1978-04-04
US4088760A (en) * 1976-06-23 1978-05-09 Richardson-Merrell Inc. Testosterone 5α-reductase inhibitors
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors

Also Published As

Publication number Publication date
GR3003768T3 (fi) 1993-03-16
CN1026236C (zh) 1994-10-19
NZ224377A (en) 1992-06-25
DK226888A (da) 1988-10-30
IE881269L (en) 1988-10-29
IL86185A0 (en) 1988-11-15
FI882007A0 (fi) 1988-04-28
CY1822A (en) 1995-10-20
NO172586B (no) 1993-05-03
EP0289327A3 (en) 1989-01-11
EP0289327B1 (en) 1991-12-18
CN1079747A (zh) 1993-12-22
US4910226A (en) 1990-03-20
FI882007A (fi) 1988-10-30
KR0131207B1 (ko) 1998-04-11
HU201956B (en) 1991-01-28
CN1030765A (zh) 1989-02-01
HU906229D0 (en) 1991-03-28
EP0289327A2 (en) 1988-11-02
CN1041054C (zh) 1998-12-09
HK22695A (en) 1995-02-24
NO881857L (no) 1988-10-31
DK175522B1 (da) 2004-11-22
ES2039278T3 (es) 1993-09-16
CA1327352C (en) 1994-03-01
ZW4488A1 (en) 1988-09-21
AU1516588A (en) 1988-11-03
IE60545B1 (en) 1994-07-27
DE3866938D1 (de) 1992-01-30
JPS6456694A (en) 1989-03-03
PT87380A (pt) 1988-05-01
PH25963A (en) 1992-01-13
HUT47131A (en) 1989-01-30
DK226888D0 (da) 1988-04-26
MY103518A (en) 1993-07-31
FI95712C (fi) 1996-03-11
PT87380B (pt) 1992-08-31
IL86185A (en) 1996-06-18
AU615439B2 (en) 1991-10-03
KR880012636A (ko) 1988-11-28
NO881857D0 (no) 1988-04-28
JPH0745511B2 (ja) 1995-05-17
NO172586C (no) 1993-08-11

Similar Documents

Publication Publication Date Title
FI95712C (fi) Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi
FI883064A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
FI880941A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten piperatsinyyli-heterosyklisten yhdisteiden valmistamiseksi
PT81965A (en) Process for the preparation of novel peptidase inhibitors
NO880162D0 (no) Fremgangsmaate ved fremstilling av nye peptidaseinhibitorer
PT87754A (pt) Process for the preparation of new amino acid derivatives
FI92934B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-deoksinojirimysiinijohdannaisten valmistamiseksi
FI951414A0 (fi) Menetelmä klavulaanihapon valmistamiseksi
FI874459A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten piperidiinijohdannaisten valmistamiseksi
FI850654A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten pleuromutilinijohdannaisten valmistamiseksi
FI93215C (fi) Menetelmä terapeuttisesti käyttökelpoisten aminoalkoksifenyylijohdannaisten valmistamiseksi
FI884910A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsopyraanijohdannaisten valmistamiseksi
FI884984A0 (fi) Menetelmä metyylitritioyhdisteiden kohdennettujen johdannaisten valmistamiseksi
FI893936A (fi) Menetelmä terapeuttisesti aktiivisten yhdisteiden valmistamiseksi sekä välituotteita
PT87642A (pt) Process for the preparation of dopamine-beta-hydroxylase inhibitors
FI902727A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI903863A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten kromaanijohdannaisten valmistamiseksi
FI902316A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia substituoituja dihydropyrrolitsiiniyhdisteitä
FI886057A (fi) Menetelmä farmaseuttisten piperidiinijohdannaisten valmistamiseksi
PT88364A (pt) Process for preparing novel hmg-coa reductase inhibitors
FI903077A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivisia R(-)-3-kinuklidinolijohdannaisia
PT88545A (pt) Process for the manufacture of benzimidazoline-2-oxo-1-carboxylic acid derivative compounds
FI92188C (fi) Menetelmä terapeuttisesti käyttökelpoisten fenoksialkyylipyrokatekolijohdannaisten valmistamiseksi
PT87236A (pt) Process for the preparation of angiogenin inhibitors
PT87079A (pt) Process for the preparation of dopamine-beta-hydroxylase inhibitors and of pharmaceutical compounds containing them

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: SMITHKLINE BECKMAN CORPORATION

MA Patent expired